
In this issue of Blood,Matsuura and colleagues provide evidence that loss of GMCSF signaling promotes leukemic progression in association with one of the most frequently observed cytogenetic abnormalities in AML, the t(8;21)(q22;q22) that generates the RUNX1-ETO fusion protein.

